1173699-31-4 Usage
Uses
Used in Oncology:
AMG-337 is used as an anticancer agent for the treatment of various malignancies, including those where the MET factor plays a significant role in their development and progression. By inhibiting the MET receptor, AMG-337 can potentially slow down or stop the growth of cancer cells and improve patient outcomes.
Used in Drug Development:
In the pharmaceutical industry, AMG-337 serves as a valuable compound for the development of targeted cancer therapies. Its selective inhibition of the MET receptor makes it a promising candidate for further research and potential incorporation into novel drug formulations aimed at treating cancer more effectively.
Used in Research:
AMG-337 is also utilized in the field of biomedical research as a tool to study the role of the MET factor in cancer biology. By understanding how AMG-337 interacts with the MET receptor and its downstream signaling pathways, researchers can gain insights into the underlying mechanisms of cancer development and identify potential therapeutic targets for future drug discovery efforts.
Biological Activity
amg 337 is a met inhibitor.met receptor with its ligand can promote cell survival, proliferation, and invasion. the activation of met signaling is a common regulator of various human cancer types, and thus, inhibition of met signaling is an promising therapeutic opportunity for the treatment of cancer.
in vitro
amg 337 could effectively inhibit met kinase activity, and amg 337 also showed great selectivity for met when tested against a panel of over 400 protein as well as lipid kinases. in addition, amg 337 was found to inhibit hgf-dependent met phosphorylation. furthermore, amg 337 could only affect the viability of two gastric cancer cell lines with amplification of the met gene. the ic50 values of amg 337 for the two sensitive cell lines was less than 50 nm, whereas over 10 μm in all other tested cell lines [1].
in vivo
in anima study, it was found that the oral administration of amg 337 led to the dose-dependent anti-tumor efficacy in met amplified gastric cancer xenograft models, which was quite consistent with the pd modulation of met signaling [1].
IC 50
< 5 nm in enzymatic assays
references
[1] paul e. hughes, et al. amg 337, a novel, potent and selective met kinase inhibitor, has robust growth inhibitory activity in met-dependent cancer models. cancer res october 1, 2014 74; 728[2] https://clinicaltrials. gov/ct2/show/nct01253707 term=amg+337&rank=1
Check Digit Verification of cas no
The CAS Registry Mumber 1173699-31-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,7,3,6,9 and 9 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1173699-31:
(9*1)+(8*1)+(7*7)+(6*3)+(5*6)+(4*9)+(3*9)+(2*3)+(1*1)=184
184 % 10 = 4
So 1173699-31-4 is a valid CAS Registry Number.
1173699-31-4Relevant academic research and scientific papers
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust in Vivo Antitumor Activity
Boezio, Alessandro A.,Copeland, Katrina W.,Rex, Karen,K Albrecht, Brian,Bauer, David,Bellon, Steven F.,Boezio, Christiane,Broome, Martin A.,Choquette, Deborah,Coxon, Angela,Dussault, Isabelle,Hirai, Satoko,Lewis, Richard,Lin, Min-Hwa Jasmine,Lohman, Julia,Liu, Jingzhou,Peterson, Emily A.,Potashman, Michele,Shimanovich, Roman,Teffera, Yohannes,Whittington, Douglas A.,Vaida, Karina R.,Harmange, Jean-Christophe
, p. 2328 - 2342 (2016/04/10)
Deregulation of the receptor tyrosine kinase mesenchymal epithelial transition factor (MET) has been implicated in several human cancers and is an attractive target for small molecule drug discovery. Herein, we report the discovery of compound 23 (AMG 337), which demonstrates nanomolar inhibition of MET kinase activity, desirable preclinical pharmacokinetics, significant inhibition of MET phosphorylation in mice, and robust tumor growth inhibition in a MET-dependent mouse efficacy model.
METHOD FOR THE PREPARATION OF (1,2,4)-TRIAZOLO(4,3-A)PYRIDINES
-
, (2015/01/16)
Disclosed herein are methods for preparing [1,2,4]triazolo[4,3-a]pyridines, particularly (R)-6-(1-(8-fluoro-6-(l-methyl4H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2- methoxyethoxy)- 1,6-naphthyridin-5(6H)-one, and precursors thereof.
